- Home
- XFOR vs VANI Comparison
XFOR vs VANI Comparison
Compare XFOR & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- VANI
- Stock Information
- Founded
- XFOR 2014
- VANI 1998
- Country
- XFOR United States
- VANI United States
- Employees
- XFOR N/A
- VANI N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- XFOR Health Care
- VANI Health Care
- Exchange
- XFOR Nasdaq
- VANI Nasdaq
- Market Cap
- XFOR 84.3M
- VANI 81.2M
- IPO Year
- XFOR N/A
- VANI 2014
- Fundamental
- Price
- XFOR $3.81
- VANI $1.67
- Analyst Decision
- XFOR Strong Buy
- VANI Strong Buy
- Analyst Count
- XFOR 3
- VANI 1
- Target Price
- XFOR $34.17
- VANI $4.00
- AVG Volume (30 Days)
- XFOR 1.4M
- VANI 312.2K
- Earning Date
- XFOR 11-12-2025
- VANI 11-12-2025
- Dividend Yield
- XFOR N/A
- VANI N/A
- EPS Growth
- XFOR N/A
- VANI N/A
- EPS
- XFOR N/A
- VANI N/A
- Revenue
- XFOR $32,774,000.00
- VANI N/A
- Revenue This Year
- XFOR $1,307.51
- VANI N/A
- Revenue Next Year
- XFOR N/A
- VANI N/A
- P/E Ratio
- XFOR N/A
- VANI N/A
- Revenue Growth
- XFOR 5721.31
- VANI N/A
- 52 Week Low
- XFOR $1.35
- VANI $0.91
- 52 Week High
- XFOR $26.83
- VANI $1.92
- Technical
- Relative Strength Index (RSI)
- XFOR 62.18
- VANI 58.63
- Support Level
- XFOR $2.96
- VANI $1.51
- Resistance Level
- XFOR $4.54
- VANI $1.92
- Average True Range (ATR)
- XFOR 0.27
- VANI 0.12
- MACD
- XFOR 0.07
- VANI 0.01
- Stochastic Oscillator
- XFOR 55.75
- VANI 53.61
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.